Company news

Idorsia Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds

August 11, 2025

Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results

July 30, 2025

Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call with our new CEO Srishti Gupta

July 23, 2025

A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans

June 30, 2025

Bondholders approve amended terms of the 2025 and 2028 convertible bonds

June 25, 2025

Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds

June 25, 2025

Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement

June 23, 2025

Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia

June 10, 2025

Idorsia publishes invitations to bondholder meetings

June 6, 2025

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025

May 28, 2025

New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability

May 21, 2025

Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders

May 2, 2025

Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset

April 30, 2025

New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine

April 29, 2025

Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond

April 16, 2025

The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension

April 9, 2025

US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement

April 9, 2025

Idorsia publishes its Annual Report 2024

March 27, 2025

US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients

March 17, 2025

Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia

March 14, 2025

Idorsia announces financial results for 2024

March 4, 2025

Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call

February 27, 2025

Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations

February 26, 2025

Idorsia and Viatris update their collaboration for selatogrel and cenerimod

February 26, 2025

Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties

February 26, 2025

Bondholders approve amended terms of the 2025 convertible bonds

February 25, 2025

← Newer news releases

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 29 decks. Every deck is listed under its year.